Mavenclad

Cladribine, the active ingredient in Mavenclad, is a purine nucleoside analog presented as a 10 mg oral tablet. It is indicated for the treatment of relapsing forms of multiple sclerosis in adult patients, helping to reduce disease activity and progression. GNH USA supplies Mavenclad as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide with a focus on quality and regulatory compliance. Our distribution network ensures reliable access across multiple regions.

Mavenclad (cladribine) is used in the disease‑modifying therapy of multiple sclerosis, targeting relapsing disease activity.

Relapsing‑remitting multiple sclerosis: reduces annual relapse rate and slows accumulation of disability. Active secondary progressive multiple sclerosis: decreases disease activity in patients with recent relapses or MRI activity. Clinically isolated syndrome with high risk of conversion: delays progression to definitive multiple sclerosis.

Cladribine may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain in the head. - Nausea: transient feeling of sickness. - Fatigue: reduced energy levels. - Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects: - Lymphopenia: marked reduction in lymphocyte count, increasing infection risk. - Herpes zoster reactivation: shingles episodes requiring antiviral therapy. - Malignancy: rare reports of cancer, requiring monitoring.

Before initiating Mavenclad, several safety considerations should be observed. - Infection monitoring: assess for signs of infection before and during therapy. - Lymphocyte count: perform baseline and periodic CBC to detect lymphopenia. - Vaccination: avoid live vaccines during treatment and for a defined period after. - Pregnancy: drug is contraindicated in pregnancy; advise effective contraception. - Renal function: adjust use in severe renal impairment. - Store at ambient temperature: keep tablets below 25 °C in original packaging, protect from moisture.

Cladribine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Live vaccines: concurrent use may cause severe infection. - Immunosuppressive agents: combined use can exacerbate lymphopenia.

Moderate Interactions (Monitor Closely): - Antiviral prophylaxis: may be needed if severe lymphopenia develops. - CYP450 substrates: cladribine is not a strong inhibitor, but monitor drugs with narrow therapeutic index. - Non‑live vaccines: timing may need adjustment to ensure efficacy.